Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3083% above fair value
$272.70−6.00 (-2.15%)
Close on Nov 18, 2026Market cap $656.47BP/E 41.4Yield 1.88%
Johnson & Johnson revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Johnson & Johnson's revenue for the twelve months ending Sep 27, 2026 was $99.34B, up 7.8% year over year. For fiscal 2025 it was $94.19B, up 6.0% from the year before. Over ten years it grew 3.0% a year on average. The highest annual figure on record is $94.19B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $94.19B | +6.0% |
| FY2024 | Dec 29, 2024 | $88.82B | +4.3% |
| FY2023 | Dec 31, 2023 | $85.16B | +6.5% |
| FY2022 | Jan 1, 2023 | $79.99B | +1.6% |
| FY2021 | Jan 2, 2022 | $78.74B | -4.7% |
| FY2020 | Jan 3, 2021 | $82.58B | +0.6% |
| FY2019 | Dec 29, 2019 | $82.06B | +0.6% |
| FY2018 | Dec 30, 2018 | $81.58B | +6.7% |
| FY2017 | Dec 31, 2017 | $76.45B | +6.3% |
| FY2016 | Jan 1, 2017 | $71.89B | +2.6% |
| FY2015 | Jan 3, 2016 | $70.07B | -5.7% |
| FY2014 | Dec 28, 2014 | $74.33B | +4.2% |
| FY2013 | Dec 29, 2013 | $71.31B | +6.1% |
| FY2012 | Dec 30, 2012 | $67.22B | +3.4% |
| FY2011 | Jan 1, 2012 | $65.03B | +5.6% |
| FY2010 | Jan 2, 2011 | $61.59B | -0.5% |
| FY2009 | Jan 3, 2010 | $61.90B | -2.9% |
| FY2008 | Dec 28, 2008 | $63.75B | +4.3% |
| FY2007 | Dec 30, 2007 | $61.10B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $25.40B | +5.9% |
| Q2 FY2026 | Jun 28, 2026 | $25.31B | +6.6% |
| Q1 FY2026 | Mar 29, 2026 | $24.06B | +9.9% |
| Q4 FY2025 | Dec 28, 2025 | $24.56B | +9.1% |
| Q3 FY2025 | Sep 28, 2025 | $23.99B | +6.8% |
| Q2 FY2025 | Jun 29, 2025 | $23.74B | +5.8% |
| Q1 FY2025 | Mar 30, 2025 | $21.89B | +2.4% |
| Q4 FY2024 | Dec 29, 2024 | $22.52B | +5.3% |
| Q3 FY2024 | Sep 29, 2024 | $22.47B | +5.2% |
| Q2 FY2024 | Jun 30, 2024 | $22.45B | +4.3% |
| Q1 FY2024 | Mar 31, 2024 | $21.38B | +2.3% |
| Q4 FY2023 | Dec 31, 2023 | $21.40B | +7.3% |
| Q3 FY2023 | Oct 1, 2023 | $21.35B | +6.8% |
| Q2 FY2023 | Jul 2, 2023 | $21.52B | +6.5% |
| Q1 FY2023 | Apr 2, 2023 | $20.89B | +5.3% |
| Q4 FY2022 | Jan 1, 2023 | $19.94B | +104.1% |
| Q3 FY2022 | Oct 2, 2022 | $20.00B | -14.3% |
| Q2 FY2022 | Jul 3, 2022 | $20.22B | -13.3% |
| Q1 FY2022 | Apr 3, 2022 | $19.84B | -11.1% |
| Q4 FY2021 | Jan 2, 2022 | $9.77B | -56.5% |
| Q3 FY2021 | Oct 3, 2021 | $23.34B | +10.7% |
| Q2 FY2021 | Jul 4, 2021 | $23.31B | +27.1% |
| Q1 FY2021 | Apr 4, 2021 | $22.32B | +7.9% |
| Q4 FY2020 | Jan 3, 2021 | $22.48B | +8.3% |
| Q3 FY2020 | Sep 27, 2020 | $21.08B | +1.7% |
| Q2 FY2020 | Jun 28, 2020 | $18.34B | -10.8% |
| Q1 FY2020 | Mar 29, 2020 | $20.69B | +3.3% |
| Q4 FY2019 | Dec 29, 2019 | $20.75B | +1.7% |
| Q3 FY2019 | Sep 29, 2019 | $20.73B | +1.9% |
| Q2 FY2019 | Jun 30, 2019 | $20.56B | -1.3% |
| Q1 FY2019 | Mar 31, 2019 | $20.02B | +0.1% |
| Q4 FY2018 | Dec 30, 2018 | $20.39B | +1.0% |
| Q3 FY2018 | Sep 30, 2018 | $20.35B | +3.6% |
| Q2 FY2018 | Jul 1, 2018 | $20.83B | +10.6% |
| Q1 FY2018 | Apr 1, 2018 | $20.01B | +12.6% |
| Q4 FY2017 | Dec 31, 2017 | $20.20B | +11.5% |
| Q3 FY2017 | Oct 1, 2017 | $19.65B | – |
| Q2 FY2017 | Jul 2, 2017 | $18.84B | – |
| Q1 FY2017 | Apr 2, 2017 | $17.77B | – |
| Q4 FY2016 | Jan 1, 2017 | $18.11B | – |
See a number that looks wrong?